CRGX (Cargo Therapeutics) FCF Margin % : 0.00% (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Cargo Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cargo Therapeutics's Free Cash Flow for the three months ended in Dec. 2024 was $-35.52 Mil. Cargo Therapeutics's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, Cargo Therapeutics's FCF Margin % for the quarter that ended in Dec. 2024 was 0.00%.

As of today, Cargo Therapeutics's current FCF Yield % is -74.59%.

The historical rank and industry rank for Cargo Therapeutics's FCF Margin % or its related term are showing as below:

CRGX's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -143.49
* Ranked among companies with meaningful FCF Margin % only.

Cargo Therapeutics FCF Margin % Historical Data

The historical data trend for Cargo Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cargo Therapeutics FCF Margin % Chart

Cargo Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Cargo Therapeutics Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial							-	-	-	-	-

Competitive Comparison of Cargo Therapeutics's FCF Margin %

For the Biotechnology subindustry, Cargo Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cargo Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cargo Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cargo Therapeutics's FCF Margin % falls into.

Cargo Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cargo Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	-145.139	/	0
	=	%

Cargo Therapeutics's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	-35.517	/	0
	=	%

Cargo Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Cargo Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Cargo Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cargo Therapeutics Inc (NAS:CRGX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1900 Alameda De Las Pulgas, Suite 350, San Mateo, CA, USA, 94403

Website

https://www.cargo-tx.com

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.